The US Food and Drug Administration has approved Imbruvica (ibrutinib) capsules for an additional indication, in the treatment-naïve patients with chronic lymphocytic leukemia (CLL).
The drug was jointly developed and commercialized by Janssen Biotech, a Johnson & Johnson (NYSE: JNJ) subsidiary, and Pharmacyclics, an AbbVie (NYSE: ABBV) company, who filed the supplemental New Drug Application for this indication last year (The Pharma Letter September 14, 2015).
In its recent financial results, AbbVie said sales of Imbruvica for full-year 2015 came in at $754 million, and the company has predicted peak annual sales of $7 billion for the drug. J&J posted revenues of $689 million from the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze